Loading
A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Daratumumab is a phase 3 interventional study registered as NCT05438043 by Janssen Research & Development, LLC, with 213 participants enrolled, started 2022-12-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Johnson & Johnson.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Shares Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Pomalidomide, Daratumumab, Lenalidomide, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/